Genmab A/S
GMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | -1.56 | 0.42 | -1.50 |
| FCF Yield | 7.81% | 4.94% | 1.87% | 1.17% |
| EV / EBITDA | 9.11 | 21.46 | 24.93 | 38.41 |
| Quality | ||||
| ROIC | 14.13% | 12.49% | 17.34% | 9.64% |
| Gross Margin | 95.42% | 98.63% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.99 | 1.31 | 0.56 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.06% | 25.09% | 12.78% | 16.19% |
| Free Cash Flow Growth | 8.28% | 94.83% | 81.93% | -67.74% |
| Safety | ||||
| Net Debt / EBITDA | -0.91 | -2.37 | -1.27 | -2.04 |
| Interest Coverage | 55.86 | 197.07 | 298.43 | 227.15 |
| Efficiency | ||||
| Inventory Turnover | 15.89 | 3.96 | 0.00 | 0.00 |
| Cash Conversion Cycle | 136.43 | 201.66 | 143.74 | 146.01 |